<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: The <z:chebi fb="0" ids="29101">Na(+)</z:chebi>-<z:chebi fb="0" ids="29103">K(+)</z:chebi>-2Cl(-) cotransporter localized in the brain vascular endothelium has been shown to be important in the evolution of <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> following experimental <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Previous in vivo studies have demonstrated that bumetanide, a selective <z:chebi fb="0" ids="29101">Na(+)</z:chebi>-<z:chebi fb="0" ids="29103">K(+)</z:chebi>-2Cl(-) cotransport inhibitor, attenuates <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-evoked <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Recently, bumetanide has been shown to also inhibit water permeability via aquaporin-4 (AQP4) expressed in Xenopus laevis oocytes </plain></SENT>
<SENT sid="3" pm="."><plain>We tested the hypothesis that the perivascular pool of AQP4 plays a significant role in the anti-<z:hpo ids='HP_0000969'>edema</z:hpo> effect of bumetanide by utilizing <z:mp ids='MP_0002169'>wild-type</z:mp> (WT) mice as well as mice with targeted disruption of alpha-syntrophin (alpha-Syn(-/-)) that lack the perivascular pool of AQP4 </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: <z:chebi fb="0" ids="6015">Isoflurane</z:chebi>-anesthetized adult male WT C57Bl6 and alpha-Syn(-/-) mice were subjected to 90 min middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) followed by 24 or 48 h of reperfusion </plain></SENT>
<SENT sid="5" pm="."><plain>Adequacy of MCAO and reperfusion was monitored with laser-Doppler flowmetry over the ipsilateral parietal cortex </plain></SENT>
<SENT sid="6" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume (tetrazolium staining), <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> (wet-to-dry ratios), and AQP4 protein expression (immunoblotting) were determined in different treatment groups in separate sets of experiments </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Bumetanide significantly attenuated <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and decreased ipsilateral hemispheric water content in WT mice compared to vehicle treatment </plain></SENT>
<SENT sid="8" pm="."><plain>In alpha-Syn(-/-) mice, bumetanide treatment had no effect on <z:mpath ids='MPATH_124'>infarct</z:mpath> volume or <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-evoked <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Bumetanide-treated WT mice had a significant attenuation of AQP4 protein expression at 48 h post-MCAO compared to vehicle-treated WT mice </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: These data suggest that bumetanide exerts its neuroprotective and anti-<z:hpo ids='HP_0000969'>edema</z:hpo> effects partly via blockade of the perivascular pool of AQP4 and may have therapeutic potential for <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> in the clinical setting </plain></SENT>
</text></document>